Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function.
Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function. Stem-cell investigations focus on whether placental mesenchymal stem cells can reduce hepatic fibrosis, promote hepatocyte regeneration, and modulate the immunological and inflammatory drivers of progression. MSCs secrete hepatoprotective factors and anti-fibrotic cytokines (TGF-β antagonists, HGF, FGF) that may arrest stellate-cell activation and collagen deposition. With 89 registered trials — the largest cohort among studied conditions — and 7 currently recruiting, the biological rationale targets the fibrotic cascade rather than curative reversal of established cirrhosis. Early clinical data suggest potential for slowing decompensation, improving synthetic function markers, and delaying transplantation.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €19,300–€24,000 (bookinghealth.com) |
| 研究的主要细胞类型 | 羊膜膜中的间充质干细胞 |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 89 · 7 recruiting now |
For the clinic's own description, see how Stem Plus describes its Liver Cirrhosis programme ↗.
Cirrhosis trials represent the most mature evidence base among stem-cell-investigated liver diseases. Published studies have documented improvements in liver synthetic function (albumin, prothrombin time), reductions in portal hypertension parameters, and enhanced hepatic blood flow following MSC infusion. Several trials reported reduced variceal bleeding incidence and slower progression to hepatic encephalopathy. However, many studies remain observational and uncontrolled; head-to-head comparisons with standard care (diuretics, beta-blockers, endoscopic banding) are sparse. Disease heterogeneity — varying aetiology (viral hepatitis, alcohol, autoimmune) and cirrhosis stage — limits generalisation of results. Long-term transplant-free survival data are limited; many patients eventually require liver transplantation despite MSC treatment.
Depending on assessment, a Liver Cirrhosis protocol may draw on:
Cirrhosis stem-cell treatment costs typically range €3,500–8,000 per cycle, reflecting the complexity of cell expansion, multiple infusions, and intensive hepatological monitoring required. Systemic intravenous infusion and hepatic artery catheterisation (in selected protocols) add procedural costs. Cell dose is often higher for cirrhosis than joint-specific conditions, increasing manufacturing expense. Hospital-based programmes with on-site cell facilities typically charge less than standalone private clinics. Ancillary costs — imaging, lab testing, gastroenterology evaluation, variceal screening — substantially increase total per-cycle expense. European university hospitals generally offer lower rates than private boutique providers.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Liver Cirrhosis cost-by-country breakdown, or compare the best countries for Liver Cirrhosis →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Liver Cirrhosis.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估